Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a col

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a desired in the second of the				
Application Number	NOT YET ASSIGNED			
Filing Date	JANUARY 23, 2004			
First Named Inventor	G. CONNOR			
Group Art Unit	NOT YET ASSIGNED			
Examiner Name	NOT YET ASSIGNED			
Attorney Docket Number	ORT-1520-USA-CNT			

	Cite No.1	U.S. Patent Document					
Examiner Initials		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Oate of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	
(D)		4,513,006		Maryanoff et al	04/23/1985		
Ca		5,242,942		Costanzo et al	009/07/1993		
P		5,384,327		Costanzo et al	01/24/1995		
(C)		5,387,700		Maryanoff et al	02/07/1995		
Ry		8,071,537		Shank	06/06/2000		
(0)		6,130,216		Antonucci et al	10/10/2000		
170)		6,191,163	81	Cottrell	02/20/2001		

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy T° **Applicant of Cited Document** Initials figures appear KindCode⁵ Office³ Number⁴ No.1 wo 99/44581 A2 Ortho-McNeil Pharmaceutical, Inc. 09/10/1999 00/50020 08/31/2000 wo **A2** University of Cincinnati wo 00/59506 A1 10/12/2000 Bristol Myers Squibb Co. 00/61139 10/19/2000 wo A1 Ortho-McNeil Pharmaceutical, Inc. wo A1 10/19/2000 00/61140 Ortho-McNeil Pharmaceutical, Inc. wo 00/76493 A1 12/21/2000 Naiarian wo 01/27128 A1 Bristol Myers Squibb Co. 04/19/2001

		i /	
Examiner Signature	Date Considered	7/21/0	35

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231,

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, e Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Application Number	NOT YET ASSIGNED
Filing Date	JANUARY 23, 2004
First Named Inventor	G. CONNOR
Group Art Unit	NOT YET ASSIGNED
Examiner Name	NOT YET ASSIGNED
Attorney Docket Number	ORT-1520-USA-CNT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²
		OSBORNE et al. Topiramate Improves Glycemic Control and Triglycerides in Animal Models, Presented to ADA. Abstracts- published on line http://www.diebetes.org/em01//AnnuelMeeting/Abstracts/AbstractSearch.eep.pp.1-11-Abstract	
		OSBORNE Figures 8 pages DEMAREST, K. ET Al. Topiramale Improves Tolerance and May Improve Insulin Sensitivity in Animal Models of Type 2 Diabetes Mellitus. Pages 1-10. Abstract	
		DEMAREST POSTER 6 PAGES Figure 1a to Pigure 4 CROOKE et al. ABSTRACT, Tepiramete Improvee Clycomic Central Independent of Weight Lace in ab/ob Nice 1 page	
		DEMAREST ET AL ABSTRACT Topimate Improvee Glucose Telerance and May Improve Insulin Sensitivity in Animel Models of Type 2 Diabetes Mellitus 1 page	_
		MARKS, Jennifor B.; The Insulin Resistance Cyndrome, The Monitor, Volume 1, No. 3, Spring 1996. OSBORNE ET AL ABSTRACT Topiramete Improves Ciyoomic Control and Triglycorides in Animal Models 1 page The Posters were presented at the Amicrican Diabetes Association Conference hold June 22 26 in Philadelphia	
(7)		SMITH, ULF ET AL, Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity. 1 page Published in Obesity Research Volume 8 (Suppl. 1) Oct 2000	
			_
		·	

	D				
Examiner /		Date	77.	110	
Signature		Considered 7	100	1/05	
			7	7	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SUBMISSION UNDER MPEP 609 D

Application Number NOT YET ASSIGNED
Filing Date JANUARY 23, 2004
First Named Inventor G. CONNOR
Group Art Unit NOT YET ASSIGNED
Examiner Name NOT YET ASSIGNED
Attorney Docket Number ORT-1520-USA-CNT

Page 1 of 1

			U.S. Patent Docume		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages of relevant figures appear
	1				
	 		<u> </u>		
	1				·
	1				
	1-1		·		

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or or relevant figures Cite Examiner Applicant of Cited Document Number⁴ KindCode⁵ Office³ appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published Cite No. Examiner Initials* PCT Search Report for PCT/US 01/50840 dated November 13, 2002

Examiner Signature	Date . Considered	7/2	1/05	
Orginatore			τ	